Form 4: 180 Life Sciences Director Granted Stock Options

A director at 180 Life Sciences Corp. was granted over 3.9 million stock options, contingent on future events and shareholder approval.

Summary

• Ryan Lewis Smith, a Director of 180 Life Sciences Corp. (ATNF), was granted 3,908,986 non-qualified stock options on July 29, 2025.
• The options have an exercise price of $2.92 per share and expire on July 29, 2035.
• These options were granted under the 2025 Supplemental Option Plan and were issued at a price of $0 as consideration for services as a director.
• While the options vested immediately, their exercisability was contingent on the closing of transactions from a July 29, 2025, Securities Purchase Agreement, which occurred on August 4, 2025.
• Exercisability is also contingent on stockholder approval of the 2025 Plan; if approval is not received by July 29, 2026, the options will be cancelled.
• Smith beneficially owns 167,181 shares of common stock directly, in addition to these options.

Sentiment

Score: 6

Explanation: The grant of stock options is generally positive for aligning director incentives, but the contingency on shareholder approval introduces a minor element of uncertainty. It's a standard compensation event.

Positives

• Grant of 3,908,986 stock options to a director aligns management incentives with shareholder value, as the options become valuable if the stock price rises above $2.92.
• The options were granted at $0 cost to the director, indicating compensation for services rendered.

Negatives

• The exercisability of the options is contingent on stockholder approval of the 2025 Plan, introducing uncertainty.
• If stockholder approval is not received by July 29, 2026, the 3,908,986 options will be cancelled, potentially impacting director compensation and retention.

Risks

• The 3,908,986 stock options granted to the director are subject to cancellation if stockholder approval of the 2025 Supplemental Option Plan is not obtained by July 29, 2026.
• The value of the options is dependent on the company's stock price exceeding the $2.92 exercise price.

Future Outlook

The future exercisability of the granted stock options is contingent on obtaining stockholder approval for the 2025 Supplemental Option Plan by July 29, 2026.

Management Comments

• Options were issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a director of the Issuer.

Industry Context

This filing reflects a standard practice in corporate governance where equity-based compensation, such as stock options, is used to incentivize directors and align their interests with long-term shareholder value. Such grants are common across various industries, particularly in biotechnology or life sciences companies, to attract and retain key talent.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential dilution if options are exercised, but also potential benefit from aligned director incentives.

Next Steps

• Stockholder approval of the 2025 Supplemental Option Plan is required by July 29, 2026, for the options to remain exercisable.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a director, which is a common practice to align management incentives with shareholder interests. It does not contain information that would fundamentally alter the investment thesis for 180 Life Sciences Corp. The contingency of shareholder approval for the option plan introduces a minor uncertainty, but it's a standard governance item. Therefore, the filing itself does not warrant a change in an existing investment position.

Keywords

180 Life Sciences Corp, ATNF, Stock Options, Director Compensation, SEC Form 4, Beneficial Ownership, Equity Grant, Corporate Governance